Literature DB >> 25610028

Evaluation of quinolone resistance in gram negative bacilli isolated from community- and hospital-acquired infections.

Ayse Bastopcu1, Halil Yazgi1, M Hamidullah Uyanik1, Ahmet Ayyildiz1.   

Abstract

OBJECTIVE: Gram negative bacilli are among the most important microbial agents involved in both hospital- and community-acquired infections. The quinolones are preferred antibacterial agents for the treatment of both community- and hospital-acquired urinary tract infections caused by gram negative bacilli because of their strong antibacterial effects, and because they can be administered both orally and parenterally. In this study, it was aimed to determine the sensitivity of gram negative bacteria isolated from both hospital- and community-acquired infections, to quinolones.
MATERIALS AND METHODS: Bacterial strains used in this study were isolated from pathologic samples of patients who were treated in different clinics or who were admitted to the polyclinics of Atatürk University Research Hospitals. Susceptibility to ciprofloxacin, levofloxacin, ofloxacin and norfloxacin was assessed for all strains included in the study via the Kirby-Bauer disk diffusion method according to CLSI criteria.
RESULTS: Of the 205 strains tested, 116 (56.5%) were from community-acquired infections, and 89 (43.5%) were from hospital-acquired infections. Resistance rates of community-origin strains against ciprofloxacin, ofloxacin and levofloxacin were 25%, whereas they were 26.7% against norfloxacin. Ciprofloxacin was the most effective quinolone (65.2%) against hospital-origin strains. E. coli was the most commonly isolated etiological agent from both community- and hospital-acquired infections.
CONCLUSION: In this study, resistance to quinolones was observed for gram negative bacilli isolated from both hospital- and community-acquired infections, with the exception of community-acquired Salmonella and Shigella. Thus, these drugs should not be used empirically in the treatment of infections caused by gram negative bacilli, and susceptibility test results should be considered when planning therapy.

Entities:  

Keywords:  Antibacterial drug resistance; Community-acquired infections; Gram-negative bacteria; Nosocomial infections; Quinolones

Year:  2008        PMID: 25610028      PMCID: PMC4261680     

Source DB:  PubMed          Journal:  Eurasian J Med        ISSN: 1308-8734


  5 in total

Review 1.  Towards a common susceptibility testing method?

Authors:  I M Gould
Journal:  J Antimicrob Chemother       Date:  2000-06       Impact factor: 5.790

2.  Increasing resistance to fluoroquinolones in escherichia coli from urinary tract infections in the netherlands.

Authors:  W Goettsch; W van Pelt; N Nagelkerke; M G Hendrix; A G Buiting; P L Petit; L J Sabbe; A J van Griethuysen; A J de Neeling
Journal:  J Antimicrob Chemother       Date:  2000-08       Impact factor: 5.790

3.  An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS Project.

Authors:  G Kahlmeter
Journal:  J Antimicrob Chemother       Date:  2003-01       Impact factor: 5.790

4.  A UK multicentre study of the antimicrobial susceptibility of bacterial pathogens causing urinary tract infection.

Authors:  D J Farrell; I Morrissey; D De Rubeis; M Robbins; D Felmingham
Journal:  J Infect       Date:  2003-02       Impact factor: 6.072

5.  Urinary tract infections in South Croatia: aetiology and antimicrobial resistance.

Authors:  Zvonimir Barisić; Andrea Babić-Erceg; Elmica Borzić; Vinko Zoranić; Vanja Kaliterna; Merica Carev
Journal:  Int J Antimicrob Agents       Date:  2003-10       Impact factor: 5.283

  5 in total
  1 in total

Review 1.  Microbial Resistance Movements: An Overview of Global Public Health Threats Posed by Antimicrobial Resistance, and How Best to Counter.

Authors:  Sameer Dhingra; Nor Azlina A Rahman; Ed Peile; Motiur Rahman; Massimo Sartelli; Mohamed Azmi Hassali; Tariqul Islam; Salequl Islam; Mainul Haque
Journal:  Front Public Health       Date:  2020-11-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.